The FDA’s vaccine-review division director, Vinay Prasad, sent an internal memo claiming that at least 10 children died “after and because of receiving” a COVID-19 vaccine. According to the memo, the deaths were likely linked to myocarditis, an inflammation of the heart muscle.
Following this revelation, the FDA reportedly plans to impose stricter requirements on future vaccines — including larger clinical trials and more stringent safety and efficacy data before approval. The agency aims to overhaul its vaccine-approval framework and reconsider long-standing practices, such as simultaneous vaccinations and existing flu-shot rules.
However, the memo—and by extension the FDA’s new stance—has drawn sharp criticism and concern from many public-health experts. Critics note the claim lacks publicly released data: the children’s ages, any preexisting conditions, and details about how the causal link was established have not been disclosed. Experts warn that relying on unverified reports, for example from the Vaccine Adverse Event Reporting System (VAERS), without robust medical review, risks undermining confidence in vaccine safety.
For now, it remains unclear whether broader public-health guidance will shift, or if additional peer-reviewed research will validate the FDA’s conclusions. Meanwhile, the agency’s announcement has ignited renewed debate over how to balance vaccine safety transparency with the need to maintain immunization coverage, especially among children.
